A61K 31/417
Imidazole-alkylamines
Official title: Imidazole-alkylamines, e.g. histamine, phentolamine
A61K31/417 (Imidazole-alkylamines) appears on 318 US grants and 512 published applications in this corpus.
Search patents in A61K- Granted patents
- 318
- Published applications
- 512
- Assignees
- 282
- Inventors
- 918
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 6 | 0 |
| 1999 | 7 | 0 |
| 2000 | 17 | 0 |
| 2001 | 8 | 4 |
| 2002 | 18 | 20 |
| 2003 | 8 | 15 |
| 2004 | 8 | 12 |
| 2005 | 4 | 14 |
| 2006 | 2 | 6 |
| 2007 | 5 | 8 |
| 2008 | 4 | 16 |
| 2009 | 2 | 18 |
| 2010 | 3 | 9 |
| 2011 | 9 | 15 |
| 2012 | 6 | 13 |
| 2013 | 9 | 27 |
| 2014 | 10 | 24 |
| 2015 | 18 | 24 |
| 2016 | 16 | 24 |
| 2017 | 24 | 21 |
| 2018 | 14 | 22 |
| 2019 | 13 | 24 |
| 2020 | 16 | 23 |
| 2021 | 11 | 24 |
| 2022 | 12 | 24 |
| 2023 | 13 | 37 |
| 2024 | 20 | 40 |
| 2025 | 15 | 19 |
| 2026 | 15 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Notch signaling inhibitors for treating obesity and metabolic disorders22 Sep 2026US 12,740,989 B2Purdue Research Foundation
- Aqueous ophthalmic solutions of phentolamine and medical uses thereof15 Sep 2026US 12,734,126 B2Opus Genetics, Inc.
- Solid state forms of Nirogacestat salts15 Sep 2026US 12,734,152 B2Assia Chemical Industries Ltd.
- Aqueous ophthalmic solutions of phentolamine and medical uses thereof1 Sep 2026US 12,721,810 B2Opus Genetics, Inc.
- Histamine receptor agonists for cancer therapy in cancer patients unresponsive to cancer immunotherapy and with elevated myeloid derived suppressor cells25 Aug 2026US 12,714,695 B2TSP Therapeutics Inc.
- Compounds and compositions for treating glucose hypometabolic disorders8 Oct 2026US 2026/0306523 A1Senovia Biosciences LLC
- Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof8 Oct 2026US 2026/0308174 A1Changsha Jingyi Pharmaceutical Technology Co., Ltd
- Dry powder formulations of epinephrine and associated methods1 Oct 2026US 2026/0294804 A1Belhaven BioPharma Inc.
- Histamine receptor agonists for cancer therapy in cancer patients unresponsive to cancer immunotherapy and with elevated myeloid derived suppressor cells1 Oct 2026US 2026/0294873 A1TSP Therapeutics Inc.
- Method of Mitigating Radiation Injury with Geranylgeranyl Transferase Inhibitors10 Sep 2026US 2026/0263421 A1BioVentures, LLC
Most cited
By later US patents
- Methods and formulations for modulating the human sexual response97US 5,731,339 AZonagen, Inc. · 1998
- Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors83US 6,270,781 B1Maxim Pharmaceuticals, Inc. · 2001
- Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin71US 5,648,355 AKOS Pharmaceutical, Inc. · 1997
- Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome62US 5,900,233 A1999
- Ophthalmic formulation which modulates dilation62US 6,515,006 B2HMT Pharma, Inc. · 2003